Rosuvastatin halts progression but not regression of atherosclerosis in low-risk patients

Use of high-dose rosuvastatin is associated with a reduction in the progression of atherosclerosis but not regression of atherosclerosis in low-risk individuals with subclinical atherosclerotic disease, said John R. Crouse III, MD, at the American College of Cardiology's 56th annual scientific session.

Use of high-dose rosuvastatin is associated with a reduction in the progression of atherosclerosis but not regression of atherosclerosis in low-risk individuals with subclinical atherosclerotic disease, said John R. Crouse III, MD, at the American College of Cardiology's 56th annual scientific session.

In the METEOR (Measuring Effects on Intima-Media Thickness: An Evaluation of Rosuvastatin) study, 984 asymptomatic persons with modest thickening of the carotid intima-media, an elevated level of low-density lipoprotein (LDL) cholesterol (mean: 154 mg/dL), and 10-year risk of coronary heart disease of <10% (by virtue of their Framingham risk score) were randomized to rosuvastatin, 40 mg/d, or placebo for 2 years.

A low-risk population was chosen so that a placebo arm could be ethically included, said Dr. Crouse, professor of medicine at Wake Forest University, Winston-Salem, N.C. "The subjects had lipid levels that currently don't require statin therapy," he said.

The primary endpoint was the annual rate of change in carotid intima-media thickness (CIMT) at 12 sites during the 2-year study period as measured by B-mode ultrasound. The hypothesis was that rosuvastatin would be associated with statistically significant regression of CIMT at the end of the 2 years.

Although rosuvastatin significantly slowed progression of maximum CIMT for the 12 carotid sites compared with placebo, statistically significant regression of atherosclerosis did not occur in the rosuvastatin-treated patients.

The maximum change in CIMT was -0.0014 mm/year in the rosuvastatin group, compared with +0.0131 mm/year in the placebo group (p <0.001). The -0.0014 mm/year change in the patients assigned to rosuvastatin was not significantly different from zero (p = 0.32).

The findings indicate that rosuvastatin halted progression but did not induce regression of atherosclerosis in a low-risk population, Dr. Crouse said. "In studying low-risk patients without advanced disease, we may have had a limited opportunity to find regression," he said. Nevertheless, the data do seem to support those of ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden), in which high-dose rosuvastatin caused regression of atherosclerosis in high-risk patients with established coronary heart disease.

The frequency of adverse events was not different between the rosuvastatin and placebo groups. Myalgia was the most common event, occurring in 12.7% of the rosuvastatin group and 12.1% of the placebo group. Elevations in alanine aminotransaminase greater than three times the upper limit of normal on two consecutive occasions occurred in 0.6% of the rosuvastatin group (4 patients) and 0.4% of the placebo group (1 patient).

Related Videos
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Beth Lown, MD
© 2023 MJH Life Sciences

All rights reserved.